Sensorion

Sensorion ROE

The Return on Equity (ROE) of Sensorion (ALSEN.PA) as of Oct 9, 2026 is -66.16 %. In the previous year, Return on Equity (ROE) was -36.00 % — a change of 83.77% (lower).

ROE

-66.16 %

YoY

83.77%

Last updated:

In 2025, Sensorion's return on equity (ROE) was -66.16 %, a 83.77% increase from the -36.00 % ROE in the previous year.

The Sensorion ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-351.82 EUR
Jan 1, 2019
-91.55 EUR
Jan 1, 2020
-15.39 EUR
Jan 1, 2021
-34.42 EUR
Jan 1, 2022
-106.12 EUR
Jan 1, 2023
-66.31 EUR
Jan 1, 2024
-36.00 EUR
Jan 1, 2025
-66.16 EUR
The Sensorion ROE history
YEARROEYoY
-66.16 %+83.77%
-36.00 %-45.70%
-66.31 %-37.52%
-106.12 %+208.34%
-34.42 %+123.66%
-15.39 %-83.19%
-91.55 %-73.98%
-351.82 %+165.85%
-132.34 %+53.39%
-86.27 %+158.95%
-33.32 %-103.49%
953.27 %—
Access this data via the Eulerpool API

Sensorion Stock analysis

What does Sensorion do? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion is one of the most popular companies on Eulerpool.

ROE Details

Decoding Sensorion's Return on Equity (ROE)

Sensorion's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Sensorion's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Sensorion's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Sensorion’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Sensorion stock

Return on Equity (ROE) of Sensorion is -66.16 % in 2025.

Return on Equity (ROE) of Sensorion changed from -36.00 % to -66.16 %, representing a 83.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Sensorion since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Sensorion with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — Sensorion

All Key Metrics — Sensorion